FAQ/Help |
Calendar |
Search |
Today's Posts |
![]() |
#1 | ||
|
|||
Member
|
Georgetown released some new pharmacokinetics and other biomarker data in a new report. Keep in mind it was just signal dose on small sample. I didn’t see anything groundbreaking here.
BPS Publications |
||
![]() |
![]() |
"Thanks for this!" says: | Betsy859 (04-23-2019), eds195 (03-14-2019), jeffreyn (03-13-2019), lab rat (03-15-2019), soccertese (03-16-2019) |
|
|
![]() |
||||
Thread | Forum | |||
Recruitment has begun for the Georgetown University "PD Nilotinib" phase 2 trial | Parkinson's Disease | |||
Georgetown Clinical Trial of Nilotinib in Alzheimer’s Disease Begins | Parkinson's Disease | |||
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parki | Parkinson's Disease | |||
Georgetown Receives FDA Clearance for Trial with Nilotinib in Alzheim | Parkinson's Disease | |||
Six month follow up on Nilotinib trial. | Parkinson's Disease |